BRPI0706726B8 - benzimidazóis 2-substituídos como modulares seletivos de receptor de andrógeno (sarms), composição farmacêutica que os compreende e processo para preparar - Google Patents
benzimidazóis 2-substituídos como modulares seletivos de receptor de andrógeno (sarms), composição farmacêutica que os compreende e processo para prepararInfo
- Publication number
- BRPI0706726B8 BRPI0706726B8 BRPI0706726A BRPI0706726A BRPI0706726B8 BR PI0706726 B8 BRPI0706726 B8 BR PI0706726B8 BR PI0706726 A BRPI0706726 A BR PI0706726A BR PI0706726 A BRPI0706726 A BR PI0706726A BR PI0706726 B8 BRPI0706726 B8 BR PI0706726B8
- Authority
- BR
- Brazil
- Prior art keywords
- androgen receptor
- sarms
- receptor modulators
- preparing
- pharmaceutical composition
- Prior art date
Links
- -1 2-substituted benzimidazoles Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000849 selective androgen receptor modulator Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76154806P | 2006-01-24 | 2006-01-24 | |
US60/761,548 | 2006-01-24 | ||
PCT/US2007/060883 WO2007087518A2 (en) | 2006-01-24 | 2007-01-23 | 2-substituted benzimidazoles as selective androgen receptor modulators (sarms) |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0706726A2 BRPI0706726A2 (pt) | 2011-04-05 |
BRPI0706726B1 BRPI0706726B1 (pt) | 2020-09-15 |
BRPI0706726B8 true BRPI0706726B8 (pt) | 2021-05-25 |
Family
ID=38180195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0706726A BRPI0706726B8 (pt) | 2006-01-24 | 2007-01-23 | benzimidazóis 2-substituídos como modulares seletivos de receptor de andrógeno (sarms), composição farmacêutica que os compreende e processo para preparar |
Country Status (26)
Country | Link |
---|---|
US (4) | US7932399B2 (pt) |
EP (1) | EP1984343B1 (pt) |
JP (1) | JP5140604B2 (pt) |
KR (1) | KR101514989B1 (pt) |
CN (1) | CN101410381B (pt) |
AU (1) | AU2007208139B2 (pt) |
BR (1) | BRPI0706726B8 (pt) |
CA (1) | CA2640046C (pt) |
CR (1) | CR10243A (pt) |
DK (1) | DK1984343T3 (pt) |
EA (1) | EA015542B1 (pt) |
EC (1) | ECSP088648A (pt) |
ES (1) | ES2402305T3 (pt) |
HR (1) | HRP20130405T1 (pt) |
IL (1) | IL192978A (pt) |
MY (1) | MY149459A (pt) |
NI (1) | NI200800206A (pt) |
NO (1) | NO341501B1 (pt) |
NZ (1) | NZ570539A (pt) |
PL (1) | PL1984343T3 (pt) |
PT (1) | PT1984343E (pt) |
RS (1) | RS52756B (pt) |
SI (1) | SI1984343T1 (pt) |
UA (1) | UA94441C2 (pt) |
WO (1) | WO2007087518A2 (pt) |
ZA (1) | ZA200807277B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0706726B8 (pt) | 2006-01-24 | 2021-05-25 | Janssen Pharmaceutica Nv | benzimidazóis 2-substituídos como modulares seletivos de receptor de andrógeno (sarms), composição farmacêutica que os compreende e processo para preparar |
US8143280B2 (en) | 2007-09-27 | 2012-03-27 | Hoffmann-La Roche Inc. | Glucocorticoid receptor antagonists |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
MX2010009162A (es) | 2008-02-22 | 2010-12-21 | Radius Health Inc | Moduladores selectivos del receptor de androgeno. |
WO2009123164A1 (ja) * | 2008-04-02 | 2009-10-08 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有するヘテロ環誘導体 |
CA2788907A1 (en) | 2010-02-04 | 2011-08-11 | Radius Health, Inc. | Selective androgen receptor modulators |
AP2012006432A0 (en) * | 2010-02-22 | 2012-08-31 | Syngenta Participations Ag | Dihydrofuran derivatives as insecticidal compounds |
HUE030072T2 (en) | 2010-05-12 | 2017-04-28 | Radius Health Inc | Therapeutic prescriptions |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
RU2666530C2 (ru) * | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
CN104703981B (zh) * | 2012-10-01 | 2017-03-29 | 霍夫曼-拉罗奇有限公司 | 作为cns活性药剂的苯并咪唑类化合物 |
RS64115B1 (sr) | 2014-03-28 | 2023-04-28 | Univ Duke | Lečenje kancera dojke upotrebom selektivnih modulatora receptora estrogena |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
KR20220035276A (ko) | 2016-06-22 | 2022-03-21 | 일립시스 파마 리미티드 | Ar+ 유방암 치료 방법 |
CA3047411A1 (en) | 2017-01-05 | 2018-07-12 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
CN108129462B (zh) * | 2018-01-19 | 2020-03-10 | 广东工业大学 | 一种二氧戊环基苯并咪唑化合物及其制备方法 |
WO2020010216A1 (en) | 2018-07-04 | 2020-01-09 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad 1901-2hcl |
AU2020292419A1 (en) * | 2019-06-12 | 2022-02-03 | The Wistar Institute | Acetyl-CoA synthetase 2 (ACSS2) inhibitors and methods using same |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE793407A (fr) * | 1971-12-28 | 1973-06-28 | Hoechst Ag | Imidazolyl - (2) -carbinols ayant une activite hypolipidemique et leur procede de preparation |
US3879393A (en) | 1973-06-18 | 1975-04-22 | Miles Lab | Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones |
US3987182A (en) * | 1974-06-17 | 1976-10-19 | Schering Corporation | Novel benzimidazoles useful as anti-androgens |
NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
US5387600A (en) * | 1992-07-30 | 1995-02-07 | Fuji Photo Film Co., Ltd. | Treating arteriosclerosis using benzimidazole compositions |
GB9310069D0 (en) | 1993-05-17 | 1993-06-30 | Zeneca Ltd | Heterocyclic compounds |
JP2000026430A (ja) * | 1998-07-02 | 2000-01-25 | Taisho Pharmaceut Co Ltd | 2、5、6−置換ベンズイミダゾール化合物誘導体 |
US6518292B1 (en) * | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
US7074806B2 (en) * | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2004048339A1 (ja) | 2002-11-22 | 2004-06-10 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
SG150533A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
AU2005243238B2 (en) * | 2004-05-03 | 2011-11-10 | Janssen Pharmaceutica N.V. | Novel indole derivatives as selective androgen receptor modulators (SARMS) |
DE102004023332A1 (de) | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
WO2006026196A2 (en) * | 2004-08-25 | 2006-03-09 | Merck & Co., Inc. | Androgen receptor modulators |
JP4953455B2 (ja) * | 2004-09-30 | 2012-06-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 選択的アンドロゲン受容体モジュレーター(sarm)として有用な新規なベンゾイミダゾール誘導体 |
CN101065363B (zh) | 2004-09-30 | 2012-05-02 | 詹森药业有限公司 | 可用作选择性雄激素受体调节剂(sarms)的新苯并咪唑衍生物 |
BRPI0706726B8 (pt) * | 2006-01-24 | 2021-05-25 | Janssen Pharmaceutica Nv | benzimidazóis 2-substituídos como modulares seletivos de receptor de andrógeno (sarms), composição farmacêutica que os compreende e processo para preparar |
US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
-
2007
- 2007-01-23 BR BRPI0706726A patent/BRPI0706726B8/pt not_active IP Right Cessation
- 2007-01-23 NZ NZ570539A patent/NZ570539A/en not_active IP Right Cessation
- 2007-01-23 EP EP07717362A patent/EP1984343B1/en active Active
- 2007-01-23 SI SI200731211T patent/SI1984343T1/sl unknown
- 2007-01-23 MY MYPI20082749A patent/MY149459A/en unknown
- 2007-01-23 JP JP2008552542A patent/JP5140604B2/ja not_active Expired - Fee Related
- 2007-01-23 CN CN2007800106841A patent/CN101410381B/zh not_active Expired - Fee Related
- 2007-01-23 AU AU2007208139A patent/AU2007208139B2/en not_active Ceased
- 2007-01-23 PL PL07717362T patent/PL1984343T3/pl unknown
- 2007-01-23 WO PCT/US2007/060883 patent/WO2007087518A2/en active Application Filing
- 2007-01-23 CA CA2640046A patent/CA2640046C/en not_active Expired - Fee Related
- 2007-01-23 RS RS20130182A patent/RS52756B/en unknown
- 2007-01-23 KR KR1020087020562A patent/KR101514989B1/ko active IP Right Grant
- 2007-01-23 PT PT77173623T patent/PT1984343E/pt unknown
- 2007-01-23 EA EA200870197A patent/EA015542B1/ru unknown
- 2007-01-23 DK DK07717362.3T patent/DK1984343T3/da active
- 2007-01-23 US US11/626,030 patent/US7932399B2/en not_active Expired - Fee Related
- 2007-01-23 ES ES07717362T patent/ES2402305T3/es active Active
- 2007-01-23 UA UAA200810555A patent/UA94441C2/ru unknown
-
2008
- 2008-07-22 IL IL192978A patent/IL192978A/en active IP Right Grant
- 2008-07-23 NI NI200800206A patent/NI200800206A/es unknown
- 2008-07-24 EC EC2008008648A patent/ECSP088648A/es unknown
- 2008-08-14 NO NO20083554A patent/NO341501B1/no not_active IP Right Cessation
- 2008-08-22 ZA ZA200807277A patent/ZA200807277B/xx unknown
- 2008-08-25 CR CR10243A patent/CR10243A/es not_active Application Discontinuation
-
2011
- 2011-03-17 US US13/050,578 patent/US8575206B2/en not_active Expired - Fee Related
-
2013
- 2013-05-08 HR HRP20130405TT patent/HRP20130405T1/hr unknown
- 2013-10-01 US US14/043,268 patent/US8802865B2/en not_active Expired - Fee Related
-
2014
- 2014-06-27 US US14/317,750 patent/US9120830B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0706726B8 (pt) | benzimidazóis 2-substituídos como modulares seletivos de receptor de andrógeno (sarms), composição farmacêutica que os compreende e processo para preparar | |
UY31183A1 (es) | Derivados de pirazinona y procesos para su preparación | |
CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
BR112015012555A2 (pt) | derivados de benzimidazol como antagonistas de ep4 | |
BR112015022566A2 (pt) | composto e composição farmacêutica | |
SV2011003855A (es) | Heteroarilos sustituidos | |
BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
BR112016009630A8 (pt) | receptores de farnesoide x, seus usos, composição farmacêutica, e combinação | |
ECSP10010296A (es) | Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina | |
CL2008000212A1 (es) | Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre | |
BR112016000909A8 (pt) | derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas | |
CL2013000714A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
CO6470845A2 (es) | Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales | |
CL2009000245A1 (es) | Compuestos derivados de heterociclil piridinilo, con actividad moduladora del receptor 5-ht6; composicion farmaceutica que los comprende y su uso para tratar la esquizofrenia, ansiedad, migrana, depresion, entre otros. | |
UY32923A (es) | Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
CL2012001366A1 (es) | Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras. | |
BRPI0907789A2 (pt) | derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos | |
PH12014501078A1 (en) | Pharmaceutical compositions and methods of use of 4-pregenen-11�-17-21-triol-3,20-dione derivatives | |
UY35073A (es) | Derivados de pirrolidinona como moduladores de GPR119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados. | |
PA8807301A1 (es) | Derivados ciclopropilamina | |
BR112012009310A2 (pt) | composto, e, composição farmacêutica | |
PA8796001A1 (es) | Moduladores tieno- y furo-pirimidina del receptor de histamina h4 | |
UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001 |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/01/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2706 DE 16-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |